Identification and Characterization of A T-Helper Peptide from Carcinoembryonic Antigen

Marta Ruiz, Hiroya Kobayashi, Juan José Lasarte, Jesús Prieto, Francisco Borrás-Cuesta, Esteban Celis, Pablo Sarobe

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Purpose: The purpose of this research was to identify promiscuous T-helper cell determinants (THd) from carcinoembryonic antigen (CEA) to be used to prime T-cell help for cancer therapy. CEA was selected because this antigen is expressed in an important variety of carcinomas. Experimental Design: Potential promiscuous THd from CEA were predicted using available computer algorithms. Predicted peptides were synthesized and tested in binding experiments to different HLA-DR molecules. Binder peptides were then used to prime T-cell responses both in vitro and in vivo. Results: Twenty 15-mer peptides from CEA were predicted to bind to different HLA-DR molecules. The promiscuous character of these peptides was demonstrated in binding experiments. Fifteen of 20 peptides tested were able to bind to HLA-DR4, but only CEA (625-639) was shown to be presented after processing of recombinant CEA. CEA (625-639) was also found to be presented by HLA-DR53. Moreover, immunization of HLA-DR4 transgenic mice with CEA (625-639) in conjunction with class I epitope OVA (257-264), induced a CTL response specific of OVA (257-264). Conclusions: CEA (625-639) might be a relevant promiscuous THd peptide for cancer therapy.

Original languageEnglish (US)
Pages (from-to)2860-2867
Number of pages8
JournalClinical Cancer Research
Volume10
Issue number8
DOIs
StatePublished - Apr 15 2004

Fingerprint

Peptide T
Carcinoembryonic Antigen
Peptides
Helper-Inducer T-Lymphocytes
HLA-DR4 Antigen
HLA-DR Antigens
T-Lymphocytes
Transgenic Mice
Epitopes
Immunization
Neoplasms
Research Design
Carcinoma
Antigens

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Ruiz, M., Kobayashi, H., Lasarte, J. J., Prieto, J., Borrás-Cuesta, F., Celis, E., & Sarobe, P. (2004). Identification and Characterization of A T-Helper Peptide from Carcinoembryonic Antigen. Clinical Cancer Research, 10(8), 2860-2867. https://doi.org/10.1158/1078-0432.CCR-03-0476

Identification and Characterization of A T-Helper Peptide from Carcinoembryonic Antigen. / Ruiz, Marta; Kobayashi, Hiroya; Lasarte, Juan José; Prieto, Jesús; Borrás-Cuesta, Francisco; Celis, Esteban; Sarobe, Pablo.

In: Clinical Cancer Research, Vol. 10, No. 8, 15.04.2004, p. 2860-2867.

Research output: Contribution to journalArticle

Ruiz, M, Kobayashi, H, Lasarte, JJ, Prieto, J, Borrás-Cuesta, F, Celis, E & Sarobe, P 2004, 'Identification and Characterization of A T-Helper Peptide from Carcinoembryonic Antigen', Clinical Cancer Research, vol. 10, no. 8, pp. 2860-2867. https://doi.org/10.1158/1078-0432.CCR-03-0476
Ruiz, Marta ; Kobayashi, Hiroya ; Lasarte, Juan José ; Prieto, Jesús ; Borrás-Cuesta, Francisco ; Celis, Esteban ; Sarobe, Pablo. / Identification and Characterization of A T-Helper Peptide from Carcinoembryonic Antigen. In: Clinical Cancer Research. 2004 ; Vol. 10, No. 8. pp. 2860-2867.
@article{10dc675af11242529e9cf69b42347b30,
title = "Identification and Characterization of A T-Helper Peptide from Carcinoembryonic Antigen",
abstract = "Purpose: The purpose of this research was to identify promiscuous T-helper cell determinants (THd) from carcinoembryonic antigen (CEA) to be used to prime T-cell help for cancer therapy. CEA was selected because this antigen is expressed in an important variety of carcinomas. Experimental Design: Potential promiscuous THd from CEA were predicted using available computer algorithms. Predicted peptides were synthesized and tested in binding experiments to different HLA-DR molecules. Binder peptides were then used to prime T-cell responses both in vitro and in vivo. Results: Twenty 15-mer peptides from CEA were predicted to bind to different HLA-DR molecules. The promiscuous character of these peptides was demonstrated in binding experiments. Fifteen of 20 peptides tested were able to bind to HLA-DR4, but only CEA (625-639) was shown to be presented after processing of recombinant CEA. CEA (625-639) was also found to be presented by HLA-DR53. Moreover, immunization of HLA-DR4 transgenic mice with CEA (625-639) in conjunction with class I epitope OVA (257-264), induced a CTL response specific of OVA (257-264). Conclusions: CEA (625-639) might be a relevant promiscuous THd peptide for cancer therapy.",
author = "Marta Ruiz and Hiroya Kobayashi and Lasarte, {Juan Jos{\'e}} and Jes{\'u}s Prieto and Francisco Borr{\'a}s-Cuesta and Esteban Celis and Pablo Sarobe",
year = "2004",
month = "4",
day = "15",
doi = "10.1158/1078-0432.CCR-03-0476",
language = "English (US)",
volume = "10",
pages = "2860--2867",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - Identification and Characterization of A T-Helper Peptide from Carcinoembryonic Antigen

AU - Ruiz, Marta

AU - Kobayashi, Hiroya

AU - Lasarte, Juan José

AU - Prieto, Jesús

AU - Borrás-Cuesta, Francisco

AU - Celis, Esteban

AU - Sarobe, Pablo

PY - 2004/4/15

Y1 - 2004/4/15

N2 - Purpose: The purpose of this research was to identify promiscuous T-helper cell determinants (THd) from carcinoembryonic antigen (CEA) to be used to prime T-cell help for cancer therapy. CEA was selected because this antigen is expressed in an important variety of carcinomas. Experimental Design: Potential promiscuous THd from CEA were predicted using available computer algorithms. Predicted peptides were synthesized and tested in binding experiments to different HLA-DR molecules. Binder peptides were then used to prime T-cell responses both in vitro and in vivo. Results: Twenty 15-mer peptides from CEA were predicted to bind to different HLA-DR molecules. The promiscuous character of these peptides was demonstrated in binding experiments. Fifteen of 20 peptides tested were able to bind to HLA-DR4, but only CEA (625-639) was shown to be presented after processing of recombinant CEA. CEA (625-639) was also found to be presented by HLA-DR53. Moreover, immunization of HLA-DR4 transgenic mice with CEA (625-639) in conjunction with class I epitope OVA (257-264), induced a CTL response specific of OVA (257-264). Conclusions: CEA (625-639) might be a relevant promiscuous THd peptide for cancer therapy.

AB - Purpose: The purpose of this research was to identify promiscuous T-helper cell determinants (THd) from carcinoembryonic antigen (CEA) to be used to prime T-cell help for cancer therapy. CEA was selected because this antigen is expressed in an important variety of carcinomas. Experimental Design: Potential promiscuous THd from CEA were predicted using available computer algorithms. Predicted peptides were synthesized and tested in binding experiments to different HLA-DR molecules. Binder peptides were then used to prime T-cell responses both in vitro and in vivo. Results: Twenty 15-mer peptides from CEA were predicted to bind to different HLA-DR molecules. The promiscuous character of these peptides was demonstrated in binding experiments. Fifteen of 20 peptides tested were able to bind to HLA-DR4, but only CEA (625-639) was shown to be presented after processing of recombinant CEA. CEA (625-639) was also found to be presented by HLA-DR53. Moreover, immunization of HLA-DR4 transgenic mice with CEA (625-639) in conjunction with class I epitope OVA (257-264), induced a CTL response specific of OVA (257-264). Conclusions: CEA (625-639) might be a relevant promiscuous THd peptide for cancer therapy.

UR - http://www.scopus.com/inward/record.url?scp=1942438127&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1942438127&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-03-0476

DO - 10.1158/1078-0432.CCR-03-0476

M3 - Article

C2 - 15102695

AN - SCOPUS:1942438127

VL - 10

SP - 2860

EP - 2867

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 8

ER -